Journal article
Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition
BMJ case reports, v 12(2), 227814
01 Feb 2019
PMID: 30765445
Abstract
Programmed cell death-1 (PD-1) inhibitors stimulate immune recognition of tumour cells in cancer patients, but have significant autoimmune side effects including pneumonitis. We report the case of a patient with asthma and mild eosinophilia who developed unusual pulmonary side effect of bronchiectasis, severe eosinophilia (absolute eosinophil count: 3200c/mm(3)) and elevated IgE levels (7050 IU/mL; normal: <164IU/mL) 4 months into therapy with the PD-1 inhibitor pembrolizumab. Aspergillus fumigatus IgG was elevated at 15.60U/mL (normal: <12.01U/mL). He responded to therapy with corticosteroids and voriconazole and was able to resume pembrolizumab thereafter with good clinical response.
Metrics
1 Record Views
Details
- Title
- Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition
- Creators
- Anthony A. Donato (Corresponding Author) - Reading HospitalRonald Krol - Reading Hospital
- Publication Details
- BMJ case reports, v 12(2), 227814
- Publisher
- Bmj Publishing Group
- Number of pages
- 3
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate); General Internal Medicine
- Web of Science ID
- WOS:000653488700080
- Scopus ID
- 2-s2.0-85061570815
- Other Identifier
- 991022161833304721